23andme
Wojcicki, cofounder and former CEO of 23andMe, is set to reacquire the company through her nonprofit, TTAM Research Institute.
Following the announcement, California Attorney General Rob Bonta issued an urgent consumer alert advising users to request the company to delete their genetic data.
The multinational pharma company will now be able to access Tempus' de-identified patient data.
The consumer genetics company reported full-year revenue came to $272 million, an 11% increase compared with the prior year.
Also: Truepill launches a COVID-19 test coverage platform for insurers, and 23andMe extends its partnership with GSK.
The test reports on the G84E mutation in the HOXB13 gene, which studies have shown increase a person’s risk of developing prostate cancer.
2022 Look Ahead
After another rough year for the healthcare system, startups are using the growth of virtual care to manage chronic conditions and expand primary care.
Also 23andMe names Dr. Joseph R. Aaron as its next chief scientific officer.
The deal is expected to close by the end of 2021.
Also: Convey Health Solutions seeks $186 million in its NYSE debut.